Novartis AG (NVS)
NYSE: NVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NVS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $284.18B
- P/E (TTM)
- 28.72
- Forward P/E
- 15.15
- EPS (TTM)
- $5.24
- Dividend yield
- 3.10% ($4.67)
- Ex-dividend date
- Mar 11, 2026
- 52-week range
- 126.50 – 170.46
- Day range
- 150.24 – 152.70
- Volume / Avg
- 2.24M / 2.18M
- Beta
- —
- Shares outstanding
- 1.89B
52-week range
NVS stock today
Shares of Novartis (NVS) finished lower on Nov 20 at $150.47, a drop of 0.50% or $0.75 per share, versus the S&P 500's 3.70% decline. Shares are 11.7% below their 52-week high of $170.46, set on Feb 27, 2026 and 18.9% above the 52-week low of $126.50, in the middle of the past year's range. NVS is up 9.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 18.2%.
At 28.7x trailing earnings, Novartis trades in line with the peer-group median of 28.9x. Its forward P/E of 15.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Novartis pays an annual dividend of $4.67 per share, a 3.10% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Novartis
Company profileNovartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease. It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Vasant Narasimhan M.D.
- Headquarters
- Basel
- Employees
- 75,267
- Website
- novartis.com
Financial highlights
Full financialsNet income was $13.98 billion (+17.1% year over year). Diluted earnings per share came in at $7.15, up from $5.87.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $13.98B | $11.94B | $14.85B | $6.96B | $24.02B |
| EPS (diluted) | $7.15 | $5.87 | $7.10 | $3.17 | $10.63 |
Analyst forecast
ForecastConsensus (11 analysts)
hold
Avg. price target
$157.10+4.41%
- Strong buy 3
- Buy 2
- Hold 4
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 27, 2026
- EPS actual vs est.
- $2.25 vs $2.25
- Surprise
- 0.00%
Dividends
Dividend history- Annual dividend
- $4.67
- Dividend yield
- 3.10%
- Last payment
- $4.77
- Ex-dividend date
- Mar 11, 2026
NVS news
All NVS news- Novartis Reaffirms Sales Targets as Drug Trial Results and FDA Talks LoomNasdaq
- Novartis Says AI Is Speeding Drug Discovery and Trials, but Clinical Payoff Remains UnprovenNasdaq
- Novartis Targets 5% Annual Sales Growth Through 2031 Despite Patent ExpirationsNasdaq
- Why is Novartis stock sliding today?Investing.com
- Novartis AG Projects +5% cc1 Sales CAGR Through 2031 and Upgrades Peak Sales Guidance for Key BrandsNasdaqNVS, BF.A
- Novartis AG (NVS) Meet Management: Growth Outlook, Cash Flow and R&D Pipeline TranscriptSeeking Alpha
- Is Immunology Emerging as Eli Lilly's Next Growth Driver?NasdaqLLY, NVS, JNJ, ABBV
- Novartis drops after updating mid-term outlookSeeking Alpha
Novartis peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AZNAstraZeneca PLC | 174.35 | -0.60% | $270.40B | vs NVS |
| MRKMerck & Company Inc. | 133.72 | +0.69% | $329.65B | vs NVS |
| ABTAbbott Laboratories | 103.00 | -0.84% | $178.39B | vs NVS |
| NVONovo Nordisk A/S | 37.82 | -2.70% | $166.69B | vs NVS |
| PFEPfizer Inc. | 27.40 | -0.51% | $156.18B | vs NVS |
| VRTXVertex Pharmaceuticals Incorporated | 515.02 | -1.08% | $130.58B | vs NVS |
| BMYBristol-Myers Squibb Company | 58.80 | +0.79% | $120.19B | vs NVS |
| SNYSanofi ADS | 46.52 | +1.00% | $111.70B | vs NVS |
Indexes, lists and sector
Novartis stock FAQ
What is Novartis's stock price today?
NVS last traded at $150.47 as of Nov 20, 4:00 PM EST, down 0.50% on the day. Prices are delayed at least 15 minutes.
Does Novartis pay a dividend?
Yes. Novartis pays $4.67 per share annually, a 3.10% yield. The most recent dividend of $4.77 had an ex-dividend date of Mar 11, 2026.
What is NVS's P/E ratio?
NVS trades at a trailing P/E ratio of 28.72 and a forward P/E of 15.15, compared with a median of 28.9 for its closest peers.
Who is Novartis's CEO?
Dr. Vasant Narasimhan M.D. is the chief executive officer of Novartis AG, which has about 75,267 employees.
Has NVS ever split its stock?
Yes. The most recent NVS stock split was a 1116-for-1000 split on Apr 9, 2019, one of 2 splits on record.
What is the NVS 52-week high?
The 52-week high for NVS is $170.46 and the 52-week low is $126.50. The stock is currently 11.7% below its high.